Royalty Pharma plc Class A Company Profile
NASDAQ: RPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 2:05 PM ET
Royalty Pharma at a glance
Royalty Pharma plc Class A (NASDAQ: RPRX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in New York, NY. Royalty Pharma is led by Mr. Pablo Legorreta and employs about 100 people. The company's shares have traded publicly since 2020.
At a market capitalization of $32.45 billion, it is considered a large-cap company. Its SEC Central Index Key (CIK) is 0001802768, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Royalty Pharma do?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Business description based on the company's public filings.
Company information
- Legal name
- Royalty Pharma plc Class A
- Ticker
- NASDAQ: RPRX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Pablo Legorreta
- Employees
- 100
- Headquarters
- 110 East 59th Street, New York, NY, United States
- Phone
- 212 883 0200
- Website
- royaltypharma.com
- IPO year
- 2020
- Market cap
- $32.45B
- SEC CIK
- 0001802768
- Latest annual report
- 10-K · Feb 11, 2026
Companies similar to Royalty Pharma
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZTSZoetis Inc. Class A | 73.66 | +2.94% | $30.44B | vs RPRX |
| ALNYAlnylam Pharmaceuticals Inc. | 222.42 | -0.89% | $29.76B | vs RPRX |
| ONCBeOne Medicines Ltd. ADR | 348.10 | -4.37% | $39.60B | vs RPRX |
| ROIVRoivant Sciences Ltd. | 34.06 | -1.99% | $24.60B | vs RPRX |
| UTHRUnited Therapeutics Corporation | 536.65 | -1.53% | $23.02B | vs RPRX |
| GMABGenmab A/S ADS | 36.10 | -1.50% | $22.20B | vs RPRX |
| INSMInsmed Incorporated | 99.00 | -2.69% | $21.62B | vs RPRX |
| VTRSViatris Inc. | 17.30 | -1.11% | $19.86B | vs RPRX |